By CJ Faucher, FNP-BC

If you’ve been dealing with bloating, reflux, fatigue, food sensitivities, brain fog, or digestive symptoms that haven’t resolved with diet changes or supplements, it’s worth understanding a research area that’s still developing: the relationship between H. pylori, a protein called zonulin, and intestinal permeability sometimes called “leaky gut.”

This connection is genuinely interesting and worth discussing with your provider. It’s also more uncertain than a lot of online content suggests, so this article tries to separate what’s well-established from what’s still hypothesis.

What Is H. pylori?

H. pylori is a spiral-shaped bacterium that colonizes the stomach lining. It’s one of the most common chronic bacterial infections worldwide, with estimates suggesting it colonizes roughly half the global population, though prevalence varies significantly by region and has been declining in many high-income countries.

Most people with H. pylori never develop symptoms. When it does cause problems, well-established effects include:

• Gastritis
• Peptic ulcers
• Acid reflux and heartburn
• Bloating, burping, nausea
• Increased risk of gastric cancer with long-term untreated infection

H. pylori has also been studied for associations with extra-digestive issues iron deficiency anemia, vitamin B12 deficiency, and certain skin conditions have the most supporting evidence. Associations with brain fog, fatigue, histamine intolerance, and broader autoimmune activity are reported in some studies but are far less consistently established, and a causal relationship hasn’t been confirmed.

What Is Zonulin?

Zonulin is a protein, first described by Dr. Alessio Fasano’s research group, that’s involved in regulating tight junctions the connections between cells lining the intestinal wall. In laboratory and animal models, increased zonulin has been linked to looser tight junctions and increased intestinal permeability.

An important caveat: there’s legitimate scientific debate about zonulin testing in practice. Commercial zonulin assays including those used in stool tests have been criticized in the literature for inconsistent results and potential cross-reactivity with other proteins (such as complement C3) that aren’t actually zonulin. This doesn’t mean the biology is wrong, but it does mean a zonulin number on a lab report should be interpreted cautiously rather than taken as a precise, validated measurement.

What Is Leaky Gut?

“Leaky gut” isn’t a formal medical diagnosis you won’t find it in standard diagnostic manuals. It’s a descriptive term for increased intestinal permeability, a real and measurable phenomenon that’s an active area of research.

Increased permeability is well-documented as a feature of several conditions, including celiac disease, inflammatory bowel disease, and some autoimmune diseases. What’s far less settled is the direction of causation: does increased permeability drive disease, or is it a downstream consequence of inflammation that’s already happening for other reasons? Most researchers in this space, including Fasano, describe it as likely bidirectional and context-dependent not a single root cause waiting to be found and fixed.

How H. pylori May Relate to Increased Permeability

Several mechanisms have been proposed and studied, mostly in lab and animal models:

Inflammation. H. pylori reliably triggers local gastric inflammation. Inflammatory signaling has been shown in some studies to affect tight junction proteins.

Immune activation. Chronic H. pylori colonization keeps the local immune system engaged. Sustained immune activity is one proposed pathway toward barrier changes, though the human evidence is more limited than the inflammation pathway.

Microbiome shifts. H. pylori can influence the broader gastric and gut microbial community. Dysbiosis has its own associations with barrier function, independent of H. pylori specifically.

Oxidative stress. H. pylori infection is associated with increased oxidative stress in gastric tissue, which has plausible but not definitively proven effects on barrier integrity in humans.

It’s worth being direct about where the evidence stands: most of the H. pylori-to-zonulin-to-leaky-gut chain described in popular health content is built from mechanisms shown in cell or animal studies, plus correlational human data. Few studies have directly tested whether treating H. pylori measurably lowers zonulin or improves clinical outcomes tied to permeability. That’s a meaningful gap between “plausible mechanism” and “established clinical pathway.”

Why Testing Broadly Can Be Useful

A reasonable clinical point holds regardless of the zonulin debate: gut symptoms are often multifactorial. Someone can have H. pylori, dysbiosis, low digestive enzyme function, and inflammation simultaneously, and a test that only checks for one of these can miss the others.

This is the actual, defensible case for comprehensive stool testing like the GI-MAP with Zonulin not that it definitively diagnoses leaky gut, but that it surveys multiple plausible contributors to symptoms in one sample, which can be useful when narrower testing hasn’t explained things. The test evaluates:

• H. pylori, including some virulence markers
• Zonulin (interpreted with the caveats above)
• Microbiome balance — commensal and opportunistic organisms
• Parasites
• Yeast and fungal markers
• Digestive function markers
• Inflammatory markers
• Secretory IgA, a marker of mucosal immune activity

Learn more about the GI-MAP with Zonulin

Who Might Consider This Testing

Broader stool testing may be worth discussing with your provider if you have persistent, unexplained:

• Bloating, reflux, or heartburn
• Altered bowel habits
• Food sensitivities or histamine-type reactions
• Fatigue or brain fog
• Skin issues
• Symptoms that haven’t responded to standard treatment or elimination diets

It’s most useful as one input alongside your full clinical picture symptoms, history, and other testing not as a standalone diagnostic tool.

If H. pylori or Increased Permeability Is Identified

H. pylori has clear, guideline-based treatment protocols (typically combination antibiotic and acid-suppression therapy), and treating a confirmed infection is well-supported regardless of what’s happening with zonulin.

For barrier support more broadly, the evidence-informed approach focuses on addressing known contributors, treating any active infection, supporting a diverse microbiome, moderating alcohol and ultra-processed food intake, and managing chronic stress rather than any single supplement or protocol marketed specifically as a “leaky gut cure.” Be skeptical of any product claiming to definitively repair intestinal permeability; the research isn’t at a point where such promises are well-supported.

The Bottom Line

H. pylori is a well-understood, treatable infection that goes beyond simple heartburn. Zonulin and intestinal permeability are real, active research areas but the science is less settled than a lot of online content implies, and zonulin testing in particular comes with measurement caveats worth knowing about.

If you’ve had persistent digestive symptoms that haven’t been explained, broader testing can be a reasonable next step ideally as part of a conversation with a physician or nurse practitioner who can interpret results in the context of your full history, rather than in isolation.

Explore the GI-MAP with Zonulin test

Need help understanding your results? Schedule a 45-minute consultation with one of our specialists by CLICKING HERE or send us an email. We’re happy to provide additional support as you navigate your results and next steps.

References

1. Fasano A. Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer. Physiol Rev. 2011;91(1):151-175.
2. Fasano A. Leaky Gut and Autoimmune Diseases. Clin Rev Allergy Immunol. 2012;42(1):71-78.
3. Camilleri M. Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans. Gut. 2019;68(8):1516-1526.
4. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori Infection: Maastricht VI/Florence Consensus Report. Gut. 2022;71(9):1724-1762.
5. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology. 2017;112(2):212-239.
6. Vancamelbeke M, Vermeire S. The Intestinal Barrier: A Fundamental Role in Health and Disease. Expert Review of Gastroenterology & Hepatology. 2017;11(9):821-834.
7. Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M. Helicobacter pylori and Extragastric Diseases. Helicobacter. 2020;25(Suppl 1):e12741.
8. Odenwald MA, Turner JR. The Intestinal Epithelial Barrier: A Therapeutic Target? Nature Reviews Gastroenterology & Hepatology. 2017;14(1):9-21.
9. Schoultz I, Keita ÅV. The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability. Cells. 2020;9(8):1909.

Disclaimer

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. It does not replace consultation with a physician, nurse practitioner, or other qualified healthcare provider. Laboratory testing can provide information to help guide care decisions but should always be interpreted within the context of your full medical history and clinical presentation. No lab test, including the GI-MAP with Zonulin, can independently diagnose or rule out any condition. If you have severe abdominal pain, GI bleeding, unexplained weight loss, difficulty swallowing, or persistent vomiting, seek prompt medical evaluation.